The Promise of Patient-Derived Preclinical Models to Accelerate the Implementation of Personalised Medicine for Children with Neuroblastoma

Overview

Journal J Pers Med

Date 2021 Apr 3

PMID 33808071

Citations 11

Authors

Elizabeth R Tucker

Sally George

Paola Angelini

Alejandra Bruna

Louis Chesler

Affiliations

Soon will be listed here.

Abstract

Patient-derived preclinical models are now a core component of cancer research and have the ability to drastically improve the predictive power of preclinical therapeutic studies. However, their development and maintenance can be challenging, time consuming, and expensive. For neuroblastoma, a developmental malignancy of the neural crest, it is possible to establish patient-derived models as xenografts in mice and zebrafish, and as spheroids and organoids in vitro. These varied approaches have contributed to comprehensive packages of preclinical evidence in support of new therapeutics for neuroblastoma. We discuss here the ethical and technical considerations for the creation of patient-derived models of neuroblastoma and how their use can be optimized for the study of tumour evolution and preclinical therapies. We also discuss how neuroblastoma patient-derived models might become avatars for personalised medicine for children with this devastating disease.

Citing Articles

Leveraging automated time-lapse microscopy coupled with deep learning to automate colony forming assay.

Klett A, Raith D, Silvestrini P, Stingl M, Bermeitinger J, Sapre A Front Oncol. 2025; 15:1520972.

PMID: 40046624 PMC: 11879803. DOI: 10.3389/fonc.2025.1520972.

Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine.

Langenberg K, van Hooff S, Koopmans B, Strijker J, Kholosy W, Ober K Eur J Cancer. 2025; 218:115275.

PMID: 39954414 PMC: 11884408. DOI: 10.1016/j.ejca.2025.115275.

Multicellular model of neuroblastoma proposes unconventional therapy based on multiple roles of p53.

Wertheim K, Chisholm R, Richmond P, Walker D PLoS Comput Biol. 2024; 20(12):e1012648.

PMID: 39715281 PMC: 11723635. DOI: 10.1371/journal.pcbi.1012648.

Recent advances in lung cancer organoid (tumoroid) research (Review).

Zhang Q, Zhang M Exp Ther Med. 2024; 28(4):383.

PMID: 39161616 PMC: 11332118. DOI: 10.3892/etm.2024.12672.

A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo.

Michael C, Mendonca-Gomes J, DePaolo C, Di Cristofano A, de Oliveira S Endocr Relat Cancer. 2024; 31(7).

PMID: 38657656 PMC: 11160356. DOI: 10.1530/ERC-23-0195.

References

Naranjo A, Irwin M, Hogarty M, Cohn S, Park J, London W . Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clin Cancer Inform. 2019; 2:1-15. PMC: 6421832. DOI: 10.1200/CCI.17.00140. View

Schramm A, Koster J, Assenov Y, Althoff K, Peifer M, Mahlow E . Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015; 47(8):872-7. DOI: 10.1038/ng.3349. View

Shultz L, Lyons B, Burzenski L, Gott B, Chen X, Chaleff S . Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174(10):6477-89. DOI: 10.4049/jimmunol.174.10.6477. View

Berkman B, Howard D, Wendler D . Reconsidering the Need for Reconsent at 18. Pediatrics. 2018; 142(2). PMC: 6317640. DOI: 10.1542/peds.2017-1202. View

Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G . Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol. 2010; 28(19):3122-30. DOI: 10.1200/JCO.2009.26.7955. View

Olsen R, Otero J, Garcia-Lopez J, Wallace K, Finkelstein D, Rehg J . MYCN induces neuroblastoma in primary neural crest cells. Oncogene. 2017; 36(35):5075-5082. PMC: 5582212. DOI: 10.1038/onc.2017.128. View

Tsuchida Y, Yokomori K, Iwanaka T, Saito S . Nude mouse xenograft study for treatment of neuroblastoma: effects of chemotherapeutic agents and surgery on tumor growth and cell kinetics. J Pediatr Surg. 1984; 19(1):72-6. DOI: 10.1016/s0022-3468(84)80020-2. View

Kroesen M, Brok I, Reijnen D, van Hout-Kuijer M, Zeelenberg I, den Brok M . Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents. Cancer Immunol Immunother. 2015; 64(5):563-72. PMC: 4412512. DOI: 10.1007/s00262-015-1663-y. View

Bruna A, Rueda O, Greenwood W, Batra A, Callari M, Batra R . A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. 2016; 167(1):260-274.e22. PMC: 5037319. DOI: 10.1016/j.cell.2016.08.041. View

10.

Benish B . Letter: "The neurocristopathies: a unifying concept of disease arising in neural crest development". Hum Pathol. 1975; 6(1):128. DOI: 10.1016/s0046-8177(75)80115-8. View

11.

Brothers K, Wilfond B . Research Consent at the Age of Majority: Preferable but not Obligatory. Pediatrics. 2018; 142(2). DOI: 10.1542/peds.2017-3038. View

12.

Moreno L, Barone G, Dubois S, Molenaar J, Fischer M, Schulte J . Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Eur J Cancer. 2020; 136:52-68. DOI: 10.1016/j.ejca.2020.05.010. View

13.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

14.

Woo X, Giordano J, Srivastava A, Zhao Z, Lloyd M, de Bruijn R . Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021; 53(1):86-99. PMC: 7808565. DOI: 10.1038/s41588-020-00750-6. View

15.

Eden C, Ju B, Murugesan M, Phoenix T, Nimmervoll B, Tong Y . Orthotopic models of pediatric brain tumors in zebrafish. Oncogene. 2014; 34(13):1736-42. PMC: 4205223. DOI: 10.1038/onc.2014.107. View

16.

Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin N . Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006; 9(5):391-403. DOI: 10.1016/j.ccr.2006.03.030. View

17.

George S, Izquierdo E, Campbell J, Koutroumanidou E, Proszek P, Jamal S . A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. Eur J Cancer. 2019; 121:224-235. PMC: 6839402. DOI: 10.1016/j.ejca.2019.07.027. View

18.

Stockmann C, Schadendorf D, Klose R, Helfrich I . The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol. 2014; 4:69. PMC: 3986554. DOI: 10.3389/fonc.2014.00069. View

19.

Mohseni M, Amanpour S, Muhammadnejad S, Sabetkish S, Muhammadnejad A, Heidari R . Establishment of a patient-derived Wilms' tumor xenograft model: a promising tool for individualized cancer therapy. J Pediatr Urol. 2013; 10(1):123-9. DOI: 10.1016/j.jpurol.2013.07.009. View

20.

Monsma D, Cherba D, Richardson P, Vance S, Rangarajan S, Dylewski D . Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance. Pediatr Blood Cancer. 2014; 61(9):1570-7. DOI: 10.1002/pbc.25039. View